Dr Sudipto BARI
Dr Zhiyong POON
Dr Xiubo FAN
Our research has focused on expanding or replacing the role of haematopoietic and mesenchymal stromal cells to enhance haematopoietic recovery after high-dose chemotherapy and transplantation as well as for the treatment of autoimmune disease.
We have developed a small molecule that can expand blood stem cells effectively and that could significantly improve the outcome of haematopoietic blood stem cell transplants, especially cord blood transplants. Interestingly, this molecule appears to encourage the growth of the most primitive blood stem cells while suppressing the growth of leukaemia cells, suggesting a potential for use in accelerating haematopoieticrecovery with simultaneous leukaemia control.
In addition, we have also developed a two-factor (2F) combination that can effectively treat graft versus host disease as well as autoimmune disease in mice. These technologies have been patented and we are currently looking to bring both treatments to clinical trials.
Finally ongoing studies have also recently identified a new role for the stromal microenvironment in the pathogenesis and disease progression of myelodysplastic syndromes, a pre-leukaemic disorder of the bone marrow. This could provide the basis for the introduction of new cancer drugs that target the stromal microenvironment and the means for identifying patient populations that may benefit from such therapy.
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000